Compare StocksMRNA vs MSFT

Moderna, Inc. (MRNA) vs Microsoft Corporation (MSFT): Which Is the Better Buy in 2026?

As of 2026-09-17, MRNA is overvalued at $156, with a DCF intrinsic value of $67 and a margin of safety of -134%. MSFT is undervalued at $496, with an intrinsic value of $752 and a margin of safety of 34%. Of the two, MSFT has the wider margin of safety.

MRNA
Moderna, Inc.
$156.09
VS
MSFT
Microsoft Corporation
$495.85

Rewards

MRNA
    MSFT
    • Microsoft Corporation has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
    • Gross margin of 67.9% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
    • Microsoft Corporation scores 84/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.

    Risks

    MRNA
    • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
    • Gross margin of -66.0% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.
    MSFT
    • FCF yield of 1.8% is below 3%, meaning the market is pricing in substantial future growth to justify the current price.
    • Insiders have sold $71.4M worth of stock in the past 3 months — significant insider liquidation.

    Key Valuation Metrics

    Learn more →
    MRNA
    MSFT
    Valuation
    $299.25M
    Free Cash Flow
    $66.99B
    0.48%
    FCF Yield
    1.82%
    N/A
    Trailing P/E
    27.64
    -34.93
    Forward P/E
    21.02
    Quality & Moat
    -122.02%
    ROIC
    20.70%
    -39.00%
    ROE
    34.04%
    -66.02%
    Gross Margin
    67.94%
    N/A
    PEG Ratio
    1.59
    Balance Sheet Safety
    Net cash
    Net Debt / Equity
    0.12
    N/A
    Interest Coverage
    N/A
    N/A
    Net Debt / EBITDA
    0.27
    0.00%
    Dividend Yield
    0.80%
    MRNA: 2Ties: 1MSFT: 6
    MRNAMSFT

    Historical Fundamentals

    Learn more →
    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    MSFT

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    MSFT
    $3.53
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $251.42B
    Δ Market Cap
    +$887.50B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    MRNA
    134.4% Overvalued
    Price is 134.4% above estimated fair value
    Current Price: $156.09
    Fair Value: $66.58
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    MSFT
    34.0% Margin of Safety
    Price is 34.0% below estimated fair value
    Current Price: $495.85
    Fair Value: $751.73
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    MRNA

    What growth rate is the market pricing in at $156?

    +39.6%
    Market-Implied FCF Growth Rate

    Market pricing in significantly higher growth than history — aggressive.

    MSFT

    What growth rate is the market pricing in at $496?

    +12.2%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +21.7%

    The market implies +12.2% Owner Earnings growth, below historical trends — potential opportunity.

    Standard FCF implies a more demanding +21.7%, reflecting heavy growth investment expected to generate future returns.

    Economic Moat Score

    Learn more →
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    MSFT
    84/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat driven primarily by revenue predictability. Reinvestment Efficiency is the area most vulnerable to competitive pressure.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

    Forensic Accounting

    Learn more →
    MRNA

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    MSFT
    -2.58
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    MRNA
    Insiders 7.3%Institutions 80.4%Retail & Other 12.2%
    No. of Institutional Holders1,097
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    MSFT
    Insiders 0.1%Institutions 75.8%Retail & Other 24.1%
    No. of Institutional Holders8,175
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    MSFT
    0
    Buys (3M)
    1
    Buys (12M)
    Total value (12M): $1.99M
    STANTON JOHN W.
    Director
    $1.99M
    @ $397.35 · 2026-02-18
    SMITH BRADFORD LEE
    President
    $1.45M
    @ $377.47 · 2025-04-23
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    MRNA
    5
    Sells (3M)
    12
    Sells (12M)
    Total value (12M): $63.50M
    HOGE STEPHEN
    President
    $11.69M
    @ $145.10 · 2026-09-15
    MOCK JAMES M
    Chief Financial Officer
    $4.69M
    @ $134.49 · 2026-09-10
    KLINGER SHANNON THYME
    Officer
    $485,766
    @ $139.95 · 2026-09-01
    BANCEL STEPHANE J
    Chief Executive Officer
    $28.72M
    @ $57.52 · 2026-08-05
    HOGE STEPHEN
    President
    $3.61M
    @ $67.60 · 2026-07-15
    HOGE STEPHEN
    President
    $2.74M
    @ $51.37 · 2026-06-15
    KLINGER SHANNON THYME
    Officer
    $173,550
    @ $50.00 · 2026-06-04
    HOGE STEPHEN
    President
    $2.58M
    @ $48.40 · 2026-05-15
    HUSSAIN SHAH ABBAS
    Director
    $264,952
    @ $46.63 · 2026-05-01
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    MOCK JAMES M
    Chief Financial Officer
    $42,986
    @ $60.12 · 2024-10-07
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    MSFT
    4
    Sells (3M)
    12
    Sells (12M)
    Total value (12M): $114.57M
    HOOD AMY E
    Chief Financial Officer
    $20.76M
    @ $498.27 · 2026-09-14
    NADELLA SATYA
    Chief Executive Officer
    $43.39M
    @ $501.46 · 2026-09-01
    ALTHOFF JUDSON
    Officer
    $4.88M
    @ $487.89 · 2026-08-05
    NUMOTO TAKESHI
    Officer
    $2.39M
    @ $496.52 · 2026-08-04
    NUMOTO TAKESHI
    Officer
    $1.81M
    @ $402.84 · 2026-06-10
    NUMOTO TAKESHI
    Officer
    $1.03M
    @ $412.45 · 2026-06-08
    ALTHOFF JUDSON
    Officer
    $7.15M
    @ $460.99 · 2026-06-01
    COLEMAN AMY
    Officer
    $519,242
    @ $411.44 · 2026-05-14
    HOGAN KATHLEEN T
    Officer
    $5.05M
    @ $409.55 · 2026-03-06
    NUMOTO TAKESHI
    Officer
    $1.36M
    @ $478.72 · 2025-12-04
    ALTHOFF JUDSON
    Officer
    $6.27M
    @ $491.52 · 2025-12-02
    SMITH BRADFORD LEE
    President
    $19.97M
    @ $518.64 · 2025-11-03
    NADELLA SATYA
    Chief Executive Officer
    $75.32M
    @ $504.78 · 2025-09-03
    NUMOTO TAKESHI
    Officer
    $2.56M
    @ $527.32 · 2025-08-12
    NUMOTO TAKESHI
    Officer
    $1.39M
    @ $463.00 · 2025-06-03
    NUMOTO TAKESHI
    Officer
    $460,008
    @ $460.01 · 2025-05-30
    HOGAN KATHLEEN T
    Officer
    $9.76M
    @ $453.77 · 2025-05-21
    ALTHOFF JUDSON
    Officer
    $7.33M
    @ $458.18 · 2025-05-19
    COLEMAN AMY
    Officer
    $5.99M
    @ $452.04 · 2025-05-15
    SMITH BRADFORD LEE
    President
    $1.68M
    @ $438.44 · 2025-05-05
    SMITH BRADFORD LEE
    President
    $35.30M
    @ $435.84 · 2025-05-05
    NUMOTO TAKESHI
    Officer
    $1.12M
    @ $447.41 · 2024-12-09
    NUMOTO TAKESHI
    Officer
    $874,634
    @ $437.32 · 2024-12-04
    NUMOTO TAKESHI
    Officer
    $1.50M
    @ $428.76 · 2024-12-02
    ALTHOFF JUDSON
    Officer
    $10.43M
    @ $417.00 · 2024-11-22
    NUMOTO TAKESHI
    Officer
    $414,720
    @ $414.72 · 2024-11-22
    YOUNG CHRISTOPHER DAVID
    Officer
    $3.05M
    @ $423.66 · 2024-11-12
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    MRNA
    FearGreed
    😐Neutral(53/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    MSFT
    FearGreed
    😐Neutral(59/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    MRNA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (53)
    MSFT
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (59)
    View MRNA Full AnalysisView MSFT Full Analysis

    Frequently Asked Questions: MRNA vs MSFT

    Is Moderna, Inc. or Microsoft Corporation more undervalued in 2026?

    Based on our discounted cash flow model, MSFT trades at a 34.0% margin of safety (intrinsic value $752 vs. price $496), compared to MRNA's -134.4% margin of safety (intrinsic $67 vs. $156).

    Which stock has a wider economic moat, Moderna, Inc. or Microsoft Corporation?

    MSFT scores 84/100 (Wide moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Moderna, Inc. in financial distress?

    MRNA's Altman Z-Score of 2.5 places it in the Grey zone, signaling elevated bankruptcy risk. MSFT scores 8.8 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, Moderna, Inc. or Microsoft Corporation?

    Microsoft Corporation (MSFT) generates a 1.8% free cash flow yield, compared to Moderna, Inc.'s 0.5%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, Moderna, Inc. or Microsoft Corporation?

    MSFT earns 20.7% ROIC versus MRNA's -122.0%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.